Skip to main content

MorphoSys Surpasses 2005 Revenue, Profit Guidance as Receipts Surge 52 Percent

NEW YORK, Feb. 3 (GenomeWeb News) - MorphoSys today said that revenue for 2005 increased 52 percent, causing total receipts and profit to surpass earlier projections, according to preliminary financial data.


Total receipts for the 12 months ended Dec. 31, 2005, increased to33.5 million ($40.2 million) from22 million year over year.


Net income surged to €4.7 million from €300,000 last year.


The company had recently forecast that net income would be3.5 million on revenues of31.5 million. But an earlier-than-planned succession of performance-based payments within existing collaborations made shortly before the end of the year helped the company surpass those projections.


MorphoSys said it will publish its audited financial statements on Feb. 24.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.